Mean arterial blood pressure throughout pregnancy in Pre (A) and Mid subgroups (B) and 24-hr urinary protein levels (C).

<p>The arrow indicates time of injection except for the β2GPI group. #P<0.05 compared with control. *p<0.05 compared with control and ApoC3+NS. ‡p<0.05 compared with control and other experiment groups. †P<0.05, compared with corresponding Mid-gestation group. Data are mean±SD, n = 10. Pre, pre-implantation. Mid, Mid-gestation.</p

Quantified expression of long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) mRNA level in liver (A) and placenta (B).

<p>*P<0.05 compared with control. †P<0.05 compared with ApoC3+L-NA. #P<0.05 compared with ApoC3+NS. Data are mean±SD, n = 10. Pre, pre-implantation. Mid, Mid-gestation.</p

Representative immunohistochemical staining of LCHAD in mouse placenta at pre-implantation (A) and mid-gestational age (B).

<p>(Original magnification ×100, scale bars 100 µm) (C): IOD of placenta immunohistochemical images in all groups. *P<0.05 compared with control. †P<0.05 compared with ApoC3+L-NA. #P<0.05 compared with ApoC3+NS. Data are mean±SD, n = 10. Pre, pre-implantation. Mid, Mid-gestation.</p

Quantified expression of p47phox mRNA and protein expression in liver (A-C) and placenta (D-F) in Mid groups.

<p>*P<0.05 compared with control. Data are mean±SD, n = 10.</p

Lipid deposition in liver tissues with Oil-red O staining at pre-implantation (A) and mid-gestational age (B).

<p>(Original magnification ×200, scale bars 50 µm) (C): Percentage of area stained in all groups. *p<0.05 compared with control. #P<0.05 compared with ApoC3+NS. †p<0.05 compared with ApoC3+L-NA. Data are mean±SD, n = 10. Pre, pre-implantation. Mid, Mid-gestation.</p

Representative immunohistochemical staining of LCHAD in mouse liver at pre-implantation (A) and mid-gestational age (B).

<p>(Original magnification ×100, scale bars 100 µm) (C): Integrated optical density (IOD) of liver immunohistochemical images in all groups. *P<0.05 compared with control. †P<0.05 compared with ApoC3+L-NA. Data are mean±SD, n = 10. Pre, pre-implantation. Mid, Mid-gestation.</p

Western blot analysis and quantification of protein level of LCHAD in liver (A-C) and placenta (D-F).

<p>*P<0.05 compared with control. #P<0.05 compared with ApoC3+NS. †P<0.05 compared with ApoC3+L-NA. Data are mean±SD, n = 10. Pre, pre-implantation. Mid, Mid-gestation.</p

Feto-placental outcomes in all treatment groups.

<p>Data are mean±SD or number (%) and n = 10 per group.</p>a<p> P<0.05 compared with Control and ApoC3+NS.</p>b<p> P<0.05 compared with corresponding Pre group.</p><p>Feto-placental outcomes in all treatment groups.</p

Assembly of Peptide with Dye Molecules for the Fabrication of Colorimetric Biosensor with Application To Diagnose HER2-Positive Breast Cancer

Peptide has been widely used for sensor design, but signal output and amplification have been challenges for such types of biosensors. In this work, a coassembly strategy has been adopted to fabricate a colorimetric biosensor with simple signal convertor and amplification. Meanwhile, by regulating the coassembly peptosome with optimal size, a sensitive and specific colorimetric biosensor can be fabricated. As a proof-of-concept, human epidermal growth factor receptor 2 (HER2) protein as the target can be specifically bound by the peptosome, and the molecular recognition events can subsequently be turned into visual signal output; thus, HER2 protein can be quantified with a limit of detection (LOD) of 3 ng mL–1. Moreover, experimental results can validate the capability of the biosensor in identifying HER2-positive and HER2-negative breast cancer patients. Therefore, this biosensor may have great potential in the field of biosensor-based in vitro diagnosis